- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: July 2024
Zilucoplan – July 2024
Zilucoplan; Solution for injection 16.6 mg in 0.416 mL (as tetrasodium) pre-filled syringe Solution for injection 23 mg in 0.574 mL (as tetrasodium) pre-filled syringe, Solution for injection 32.4 mg in 0.810 mL (as tetrasodium) pre-filled syringe; Zilbrysq®
Last updated
30 May 2025
